M. Montanari

Prognostic and Predictive Role of Neutrophil to lymphocyte Ratio in Second Line Immunotherapy of Non-small Cell Lung Cancer

G. Rossi, C. Bennati, S. Tamberi, 2021, International Journal of Clinical Oncology and Cancer Research.

Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer

E. Scarpi, D. Amadori, S. Carloni, 2012, Tumori.

Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.

E. Scarpi, D. Amadori, S. Carloni, 2012, Tumori.

PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.

V. Conteduca, U. de Giorgi, E. Bianchi, 2015, Clinical genitourinary cancer.

Reversible cerebral ischemias: A comparative analysis of risk factors in TIAs and in RINDs

G. Gambina, L. Deotto, G. Preite, 1984, The Italian Journal of Neurological Sciences.

Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.

C. Dazzi, M. Papi, C. Casanova, 2013, Clinical lung cancer.

Activity of different anthracycline formulations in hormone‐refractory prostate cancer cell lines: Role of golgi apparatus

D. Amadori, A. Tesei, R. Silvestrini, 2011, Journal of cellular physiology.

Phase II trial of nonpegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study.

D. Amadori, S. Carloni, R. Mattioli, 2010 .